secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001558370-22-013169
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune Q2 net loss $20.1M ($0.42/share); cash $184.8M; pemvidutide Phase 1b data mid-Sept
--------------------------------------------------------------------------------

- Net loss of $20.1M ($0.42 per share) for Q2 2022 vs $24.8M ($0.60) in Q2 2021, which included $8.1M impairment.
- Cash, equivalents, and short-term investments $184.8M at June 30, 2022.
- R&D expenses $16.0M in Q2 2022, up from $13.3M, primarily on pemvidutide development.
- Pemvidutide Phase 1b obesity/NAFLD topline data expected mid-September 2022; Phase 2 MOMENTUM interim analysis (160 subjects) expected Q1 2023.
- HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; data expected H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000155837022013169/0001558370-22-013169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000155837022013169/alt-20220811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-013169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer